Novartis Pharma AG: Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease

Related Keywords

United States ,France ,San Antonio ,Texas ,Lugano ,Ticino ,Switzerland ,Chicago ,Illinois ,Paris ,France General ,Spain ,Norway ,Barcelona ,Comunidad Autonoma De Cataluna ,America ,American ,Samir Shah ,Nicole Zinsli Somm ,Richard Jarvis ,Isabella Zinck ,Satoshi Sugimoto ,Dennisj Slamon ,Shreeram Aradhye ,Marlena Abdinoor ,Julie Masow ,Parag Mahanti ,Fran Visco ,Mary Carmichael ,Michael Meo ,Sloan Simpson ,Jonsson Comprehensive Cancer Center ,Twitter ,National Breast Cancer Coalition ,American Society Of Clinical Oncology ,American Cancer Society ,Steering Committee ,European Commission ,Astex Pharmaceuticals ,American Society Of Clinical Oncology Annual Meeting ,European Society For Medical Oncology ,Exchange Commission ,Global Drug Development ,Drug Administration ,Akershus University Hospital ,Novartis Institutes For Biomedical Research ,Translational Research In Oncology ,European Society Of Medical Oncology Congress ,Novartis ,Pfizer Inc ,Vestre Viken Hospital ,Clinical Translational Research ,Clinical Oncology ,Translational Research ,Comprehensive Cancer Center ,Executive Director ,Chief Medical Officer ,Standardized Definitions ,Efficacy End Points ,Clinical Benefit Scale ,United States Food ,Novartis Institutes ,Biomedical Research ,Prescribing Information ,American Society ,Clinical Oncology Annual Meeting ,European Society ,Medical Oncology ,Medical Oncology Breast Cancer ,Advanced Breast ,New England Journal ,Medical Oncology Congress ,England Journal ,San Antonio Breast Cancer Symposium ,Practice Guidelines ,Published March ,Published April ,Vestre Viken Hospital Trust ,Neoadjuvant Treatment ,Dharma ,Kisqali ,Ignificantly ,Educed ,Risk ,Recurrence ,Cross ,Road ,Population ,Patients ,Early ,Breast ,Dancer ,Linically ,Meaningful ,Benefit ,Consistent ,Subgroups ,